Ginkgo biloba fails drug test | Science News

Support Science Journalism

Science News is a nonprofit.

Support us by subscribing now.


Ginkgo biloba fails drug test

The herb fares no better than placebos in preventing Alzheimer’s disease

2:51pm, November 18, 2008

The supplement Ginkgo biloba has failed to ward off Alzheimer’s disease or other forms of dementia any better than a placebo in a long-term trial, researchers report in the Nov. 19 Journal of the American Medical Association (JAMA).

“This is tremendously disappointing,” says study coauthor Steven DeKosky, a neurologist at the University of Virginia School of Medicine in Charlottesville.

DeKosky has good reason to feel let down. In earlier laboratory tests, ginkgo extract showed an ability to protect brain cells from the very sort of problems that occur in Alzheimer’s patients. In animal tests, the herb inhibited the clumping — or formation of plaques — of the protein amyloid-beta. These plaques are widely assumed to play a role in Alzheimer’s. Ginkgo also has antioxidant properties, further boosting its appeal.

But the new, eight-year study, the largest clinical trial ever specifically designed t

This article is only available to Science News subscribers. Already a subscriber? Log in now.
Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content